HK1251972A1 - K-ras調節劑 - Google Patents
K-ras調節劑Info
- Publication number
- HK1251972A1 HK1251972A1 HK18111290.4A HK18111290A HK1251972A1 HK 1251972 A1 HK1251972 A1 HK 1251972A1 HK 18111290 A HK18111290 A HK 18111290A HK 1251972 A1 HK1251972 A1 HK 1251972A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ras modulators
- ras
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562157915P | 2015-05-06 | 2015-05-06 | |
US201562158356P | 2015-05-07 | 2015-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1251972A1 true HK1251972A1 (zh) | 2019-05-10 |
Family
ID=57218009
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18111150.3A HK1251485A1 (zh) | 2015-05-06 | 2018-08-30 | K-ras調節劑 |
HK18111290.4A HK1251972A1 (zh) | 2015-05-06 | 2018-09-04 | K-ras調節劑 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18111150.3A HK1251485A1 (zh) | 2015-05-06 | 2018-08-30 | K-ras調節劑 |
Country Status (17)
Country | Link |
---|---|
US (2) | US10857140B2 (zh) |
EP (1) | EP3291813A4 (zh) |
JP (1) | JP6771023B2 (zh) |
KR (1) | KR20180017013A (zh) |
CN (1) | CN107847495A (zh) |
AU (1) | AU2016258192B2 (zh) |
BR (1) | BR112017023821A2 (zh) |
CA (1) | CA2983927A1 (zh) |
CL (2) | CL2017002786A1 (zh) |
EA (1) | EA201792443A1 (zh) |
EC (1) | ECSP17073743A (zh) |
HK (2) | HK1251485A1 (zh) |
IL (1) | IL255417A (zh) |
MA (1) | MA42061A (zh) |
MX (1) | MX2017014163A (zh) |
PH (1) | PH12017501999A1 (zh) |
WO (1) | WO2016179558A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
CN109843856B (zh) | 2016-05-18 | 2023-05-02 | 米拉蒂治疗股份有限公司 | Kras g12c抑制剂 |
SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
KR20200100632A (ko) | 2017-11-15 | 2020-08-26 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
WO2019204505A2 (en) * | 2018-04-18 | 2019-10-24 | Theras, Inc. | K-ras modulators with a vinyl sulfonamide moiety |
US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス, インコーポレイテッド | Kras g12c阻害剤 |
WO2020198488A1 (en) * | 2019-03-26 | 2020-10-01 | University Of Massachusetts | Therapeutic targets for oncogenic kras-dependent cancers |
MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
JP2022548791A (ja) | 2019-09-24 | 2022-11-21 | ミラティ セラピューティクス, インコーポレイテッド | 組み合わせ療法 |
CN110981943B (zh) * | 2019-12-02 | 2021-08-03 | 清华大学 | 多肽及其在制备药物中的用途和药物 |
US11702418B2 (en) | 2019-12-20 | 2023-07-18 | Mirati Therapeutics, Inc. | SOS1 inhibitors |
CA3175481A1 (en) * | 2020-04-27 | 2021-11-04 | Verastem, Inc. | Methods of treating abnormal cell growth |
TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3131527A1 (de) | 1981-08-08 | 1983-02-24 | Kali-Chemie Pharma Gmbh, 3000 Hannover | 1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
JPS61227567A (ja) | 1985-04-01 | 1986-10-09 | Eisai Co Ltd | 1,4−ジヒドロピリジン誘導体 |
DK626889A (da) | 1988-12-16 | 1990-06-17 | Roussel Uclaf | Indanderivater, deres fremstilling samt laegemidler med indhold deraf |
IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
WO1996006078A1 (en) | 1994-08-24 | 1996-02-29 | Pfizer Pharmaceuticals Inc. | N-(2-(pyrrolidinyl-1)-1-phenylethyl)acetamides as kappa receptor antagonists |
US5475109A (en) * | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
US5631251A (en) | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | 5-cyclopropyl-1,4 benzodiazepine-2-ones |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
DE60033809T2 (de) | 1999-06-04 | 2007-12-06 | Astrazeneca Ab | Inhibitoren von metalloproteinasen |
KR20020060160A (ko) | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
US20030207910A1 (en) | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
WO2003004474A1 (en) | 2001-07-06 | 2003-01-16 | Syngenta Participations Ag | Pesticidally active aminoacetonitriles |
MXPA05003632A (es) | 2002-10-11 | 2005-06-03 | Astrazeneca Ab | Derivados de piperidina 1, 4-disustituidos y su uso como inhibidores de 11-beta-hidroesteroide deshidrogenasa humana de tipo 1 (11betahsd1). |
CA2517629C (en) | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US20050119266A1 (en) | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
GB0326029D0 (en) * | 2003-11-07 | 2003-12-10 | Astrazeneca Ab | Chemical compounds |
WO2005047286A1 (ja) | 2003-11-13 | 2005-05-26 | Ono Pharmaceutical Co., Ltd. | スピロ複素環化合物 |
US20080058356A1 (en) | 2003-12-15 | 2008-03-06 | Neurocrine Biosciences, Inc. | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists |
JP2007517905A (ja) | 2004-01-16 | 2007-07-05 | ワイス | アゾールを含有するベータアミロイド産生のヘテロ環式スルホンアミド阻害剤 |
WO2007093540A1 (en) | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Benzoyl-piperidine derivatives as 5ht2/d3 modulators |
WO2007109154A2 (en) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
WO2009015237A1 (en) | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
AR074790A1 (es) | 2008-12-19 | 2011-02-09 | Novartis Ag | Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente. |
WO2010138758A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
WO2013155223A1 (en) * | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Compositions and methods for treating cancer |
EP2698367A1 (en) | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
UY35464A (es) * | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
JP6473133B2 (ja) | 2013-03-15 | 2019-02-20 | アラクセス ファーマ エルエルシー | Krasg12cの共有結合性阻害剤 |
WO2015048570A2 (en) | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
AU2016244017B2 (en) * | 2015-04-03 | 2020-07-23 | Nant Holdings Ip, Llc | Compositions and methods of targeting mutant K-ras |
MX2017014163A (es) | 2015-05-06 | 2018-08-15 | Univ California | Moduladores de k-ras. |
TWI751155B (zh) | 2016-04-15 | 2022-01-01 | 美商雅酶股份有限公司 | 經胺取代之芳基或雜芳基化合物 |
SG11201909570PA (en) | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
-
2016
- 2016-05-06 MX MX2017014163A patent/MX2017014163A/es unknown
- 2016-05-06 EA EA201792443A patent/EA201792443A1/ru unknown
- 2016-05-06 JP JP2018510695A patent/JP6771023B2/ja active Active
- 2016-05-06 EP EP16790206.3A patent/EP3291813A4/en not_active Withdrawn
- 2016-05-06 BR BR112017023821A patent/BR112017023821A2/pt not_active Application Discontinuation
- 2016-05-06 WO PCT/US2016/031344 patent/WO2016179558A1/en active Application Filing
- 2016-05-06 CN CN201680037365.9A patent/CN107847495A/zh active Pending
- 2016-05-06 US US15/571,475 patent/US10857140B2/en active Active
- 2016-05-06 CA CA2983927A patent/CA2983927A1/en not_active Abandoned
- 2016-05-06 MA MA042061A patent/MA42061A/fr unknown
- 2016-05-06 AU AU2016258192A patent/AU2016258192B2/en not_active Ceased
- 2016-05-06 KR KR1020177035079A patent/KR20180017013A/ko unknown
-
2017
- 2017-11-02 PH PH12017501999A patent/PH12017501999A1/en unknown
- 2017-11-03 IL IL255417A patent/IL255417A/en unknown
- 2017-11-03 CL CL2017002786A patent/CL2017002786A1/es unknown
- 2017-11-06 EC ECIEPI201773743A patent/ECSP17073743A/es unknown
-
2018
- 2018-08-30 HK HK18111150.3A patent/HK1251485A1/zh unknown
- 2018-09-04 HK HK18111290.4A patent/HK1251972A1/zh unknown
- 2018-11-21 CL CL2018003316A patent/CL2018003316A1/es unknown
-
2020
- 2020-10-28 US US17/082,125 patent/US11541044B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2017014163A (es) | 2018-08-15 |
JP2018519357A (ja) | 2018-07-19 |
WO2016179558A8 (en) | 2017-11-16 |
CA2983927A1 (en) | 2016-11-10 |
ECSP17073743A (es) | 2018-03-31 |
AU2016258192A1 (en) | 2017-11-16 |
IL255417A (en) | 2018-01-31 |
CN107847495A (zh) | 2018-03-27 |
EP3291813A4 (en) | 2019-01-02 |
JP6771023B2 (ja) | 2020-10-21 |
US20180289683A1 (en) | 2018-10-11 |
US10857140B2 (en) | 2020-12-08 |
EA201792443A1 (ru) | 2018-10-31 |
WO2016179558A1 (en) | 2016-11-10 |
HK1251485A1 (zh) | 2019-02-01 |
KR20180017013A (ko) | 2018-02-20 |
PH12017501999A1 (en) | 2018-04-02 |
US11541044B2 (en) | 2023-01-03 |
BR112017023821A2 (pt) | 2018-07-31 |
CL2018003316A1 (es) | 2019-03-15 |
AU2016258192B2 (en) | 2021-07-29 |
EP3291813A1 (en) | 2018-03-14 |
US20210196695A1 (en) | 2021-07-01 |
CL2017002786A1 (es) | 2018-06-22 |
MA42061A (fr) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251972A1 (zh) | K-ras調節劑 | |
DK3256579T3 (en) | Cysteinprotease | |
ZA201707966B (en) | Ccr2 modulators | |
DK3256580T3 (en) | Cysteinprotease | |
DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
PL3303291T3 (pl) | Modulatory ROR-gamma | |
PL3303293T3 (pl) | Modulatory ROR-gamma | |
PL3303290T3 (pl) | Modulatory ROR-gamma | |
PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
IL266261A (en) | ror-gamma modulators | |
AU361999S (en) | Ballustrade | |
DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
PT3370756T (pt) | Combinação de canrenoato e exenatido | |
DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
DK3242882T3 (en) | Cgrp-antagonistpeptider | |
GB201519573D0 (en) | Combination | |
HK1243457A1 (zh) | 通道調節劑 | |
AU5516P (en) | LEP08 Lepidosperma squamatum | |
GB201522365D0 (en) | Concept abcd12 | |
AU5511P (en) | PTK647 Epichloe coenophiala | |
GB201522799D0 (en) | Combination | |
AU366552S (en) | Nutblock | |
GB201521901D0 (en) | Combination | |
GB201518520D0 (en) | Concept ABCD4 | |
GB201517052D0 (en) | Forty three |